Theravance gets a fresh start

Theravance’s latest move, to sell off the royalties it gets from GSK’s Trelegy Ellipta to Royalty Pharma, looks like a necessary one. With $1.1bn up front, the troubled company will get to repay its debts, return some money to shareholders, and even have something left for future drug development.